Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of “Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned a consensus rating of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $57.10.

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Leerink Partners increased their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Citigroup boosted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th.

Insider Buying and Selling

In other news, COO Peter Radovich sold 1,998 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the transaction, the chief operating officer now owns 27,015 shares of the company’s stock, valued at $1,156,782.30. This represents a 6.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,737 shares of company stock valued at $556,098 over the last ninety days. Insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently modified their holdings of MIRM. Quest Partners LLC grew its holdings in Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares during the period. Amalgamated Bank increased its position in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after buying an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after buying an additional 318 shares during the period. ProShare Advisors LLC bought a new position in Mirum Pharmaceuticals during the second quarter worth about $213,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Mirum Pharmaceuticals in the third quarter valued at about $215,000.

Mirum Pharmaceuticals Trading Down 0.1 %

Shares of MIRM opened at $42.00 on Thursday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $48.89. The stock has a 50 day simple moving average of $42.86 and a 200-day simple moving average of $40.61.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the company posted ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. On average, sell-side analysts predict that Mirum Pharmaceuticals will post -1.46 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.